Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ad4-mgag

Vaccine (Adenoviral vector) · Immune activation, directed at HIV Gag · developed by Emergent BioSolutions

Phase 1 Most advanced trial (none active)
EBS Developer
1 Registered trials

What is Ad4-mgag?

Ad4-mgag is a live replication-competent adenovirus type-4 vector vaccine encoding a mosaic HIV Gag antigen, delivered orally via enteric-coated capsules to elicit immune responses against HIV.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Adenoviral vector)
Targets
HIV Gag (antigen)
Mechanism
Immune activation, directed at HIV Gag
Therapy area
Infectious disease
Developer
Emergent BioSolutions (EBS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02771730 Phase 1 Healthy Volunteer Terminated EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteerHIV Vaccine

More from Emergent BioSolutions

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Ad4-mgag

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.